Fig. 5: In vivo targeting efficiency and retention effect of nanomedicines. | Nature Communications

Fig. 5: In vivo targeting efficiency and retention effect of nanomedicines.

From: MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition

Fig. 5

a In vivo imaging of mice at 1, 2, 4, 8, 12, 24 h post intravenous injection. b Ex vivo imaging of tumors. c Semi-quantification of major organs and tumors at 24 h post intravenous injection (n = 4 mice). d In vivo fluorescent imaging of mice at 5 min, 4, 8, 12, 24, 36, and 48 h post intra-tumoral injection. e Ex vivo imaging of tumors at 48 h. f Semi-quantification of tumors (n = 4 mice). g Fluorescent distribution of frozen sections of tumors (scale bar = 100 μm). All data are presented as mean ± SD. Two-tailed Student’s t test and One-way analysis of variance (ANOVA) with a Tukey post hoc test were used for the statistical comparison between the two groups and among multiple groups, respectively. A significant difference was considered when the p value was < 0.05. Source data are provided as a Source Data file.

Back to article page